Journal: PLOS Pathogens
Article Title: Bacterial infection promotes tumorigenesis of colorectal cancer via regulating CDC42 acetylation
doi: 10.1371/journal.ppat.1011189
Figure Lengend Snippet: (A) CDC42 K153 acetylation is regulated by SIRT family deacetylases. HEK293T cells transfected with Flag-CDC42 were treated with the deacetylase inhibitors TSA (2 μM) and NAM (10 mM) for 16 h before harvesting. K153 acetylation was determined by IP/WB. (B) SIRT2 decreases K153 acetylation in vivo . Overexpression of SIRT2 significantly decreases K153 acetylation. Flag-CDC42 was co-transfected with or without HA-SIRT2 into HEK293T cells, and K153 acetylation was analyzed by IP with anti-Flag antibody and WB with anti-K153Ac antibody. (C) SIRT2 decreases K153 acetylation in vitro . Purified GST-CDC42 protein was incubated with the cell lysate of HEK293T cells expressing HA-SIRT2 or the control vector. K153 acetylation was determined by the GST pull-down assay, followed by WB with anti-K153Ac antibody. (D) A reduced acetylation of K153 was shown in AK7-treated cells. Flag-CDC42 was co-transfected with or without HA-SIRT2, followed by treatment with the SIRT2 specific inhibitor AK7 (10 μM) or dimethyl sulfoxide (DMSO) (as a negative control) for 16 h. K153 acetylation was then determined by IP/WB. SIRT2 knockdown increases K153 acetylation. Flag-CDC42 was transfected with or without HA-PAK4 into HEK293T cells with SIRT2 knocked down, and the cells were infected with S . Typhimurium. Salmonella infection failed to reduce K153 acetylation and binding between CDC42 with PAK4 in the SIRT2 knockdown cells. Cell lysates were used for IP with anti-Flag antibody. K153 acetylation was then analyzed by WB with anti-K153Ac antibody (E), and the association between CDC42 and PAK4 was determined by WB (F).
Article Snippet: Anti-CDC42 (#10155-1-AP, 1:1000 for WB), anti-PAK4 (#14685-1-AP, 1:1000 for WB), anti-PAK1(#21401-1-AP, 1:1000 for WB), monoclonal anti-GST(#66001-2-Ig, 1:10000 for WB), polyclonal anti-HA (#51064-2-AP, 1:5000 for WB), monoclonal anti-SIRT2 (#66410-1-IG, 1:10000 for WB), anti-beta tubulin (#10094-1-AP, 1:2000 for WB), MMP-2 (#10373-2-AP, 1:1000 for WB), MMP-9 (#10375-2-AP, 1:1000 for WB) were purchased from Proteintech; Monoclonal anti-HA (#AB0025, 1:5000 for WB); E-cadherin (#BS1098, 1:1000 for WB) were from Bioworld; Monoclonal anti-CDC42 (#sc-8401, 2 μg per 500 μg of total protein for Immunoprecipitation), anti-p-PAK4 (sc-135775, 1:200 for WB) were from Santa Cruz; Anti-p-PAK1 (#2601, 1:1000 for WB), anti-p-AKT (#4060, 1:1000 for WB), anti-AKT (#4691, 1:1000 for WB), anti-p-ERK (#9101, 1:1000 for WB), anti-ERK (#4370, 1:1000 for WB), anti-p-p38 (#9211, 1:1000 for WB), anti-p38 (#9212, 1:1000 for WB), anti-p-JNK (#9251, 1:1000 for WB), anti-ERK (#9252, 1:1000 for WB), anti-caspase 3 (#14220, 1:1000 for WB) and anti-PARP (#9542, 1:1000 for WB) were from Cell Signaling Technology; Monoclonal anti-HA (#M180, 1:500 for Immunoprecipitation), monoclonal anti-Flag (#M185, 1:500 for Immunoprecipitation), polyclonal anti-Flag (#PM020, 1:1000 for WB) and deacetylase inhibitors TSA (#9950) were from MBL; Deacetylase inhibitor NAM (#N1651) was from APExBIO; CBP/p300 inhibitor A-485 (#N1651) was from MCE; SIRT2 inhibitor AK7 (#4754–10) was from Tocris Bioscience; Staurosporine (#abs810006) was from Absin; Polybrene (#H9268) and puromycin (#P8833) were from Sigma-Aldrich.
Techniques: Transfection, Histone Deacetylase Assay, In Vivo, Over Expression, In Vitro, Purification, Incubation, Expressing, Control, Plasmid Preparation, Pull Down Assay, Negative Control, Knockdown, Infection, Binding Assay